Cogent Biosciences, Inc.
15
4
7
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
26.7%
4 terminated/withdrawn out of 15 trials
33.3%
-53.3% vs industry average
7%
1 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Role: lead
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Role: lead
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Role: lead
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Role: lead
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Role: lead
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Role: lead
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Role: lead
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Role: lead
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Role: collaborator
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Role: lead
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Role: lead
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Role: lead
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Role: lead
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Role: lead
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Role: lead
All 15 trials loaded